Entyvio 108 mg 2 pre-filled pens (refrigerated)

4079.15

Out of Stock

Product description

Product description: Entyvio contains the active substance Vedolizumab belongs to a group of biological medicines called monoclonal antibodies (MAbs). How does Entyvio work: Entyvio works by preventing the protein on the surface of white blood cells that causes ulcerative colitis and Crohn's disease. This reduces inflammation. What is Entyvio used for: Entyvio is used to treat signs and symptoms in adults who suffer from: moderate to severe active ulcerative colitis, moderate to severe active Crohn's disease. Ulcerative colitis: Ulcerative colitis is a disease that causes inflammation of the colon. If you have ulcerative colitis, you will be given other medicines first. If you do not respond well enough or cannot tolerate these medicines, your doctor may give you Entyvio to reduce your disease signs and symptoms. Crohn's disease: Crohn's disease is a disease that causes inflammation of the digestive system. If you have Crohn's disease, you will first receive other medicines. If you do not respond well enough or cannot tolerate these medicines, your doctor may give you Entyvio to reduce your disease signs and symptoms. Warnings and precautions: Do not use Entyvio: if you are allergic to Vedolizumab or any other ingredients of this medicine. if you have an active serious infection — such as tuberculosis (TB), sepsis, severe diarrhea and vomiting (gastroenteritis), and neurological inflammation. Talk to your doctor or pharmacist or nurse before using Entyvio. Inform your doctor or pharmacist or nurse immediately before using this medicine and during treatment between doses: if you experience blurred vision or loss of vision or double vision or difficulty speaking or weakness of arms or legs or changes in your walking or balance problems or persistent numbness or decreased sensation or tingling or memory loss or confusion. These may be symptoms of a serious brain condition called progressive multifocal leukoencephalopathy (PML). If you have an infection or think you have an infection — symptoms include chills or shivering or persistent cough or fever. Some types of infections can become serious and life-threatening if left untreated. If you experience signs of an allergic reaction such as wheezing or breathing problems or hives or itching or swelling or dizziness. For more detailed information, see allergic reactions in section 4. If you are about to receive vaccines, or have recently received a vaccine. Entyvio can affect how you react to the vaccine. If you have cancer, tell your doctor. Your doctor will decide if you can still receive Entyvio. If you do not feel better, it may take up to 14 weeks for Vedolizumab to work in some patients with very active Crohn's disease. Children and adolescents: Not recommended for children and adolescents (under 18 years) due to insufficient information about the use of this medicine in this age group. Pregnancy and breastfeeding: Talk to your doctor before receiving this medicine if you are pregnant or breastfeeding, or think you are pregnant, or planning to become pregnant. Pregnancy: The effect of Entyvio on pregnant women is unknown. Therefore, this medicine is not recommended during pregnancy. You and your doctor should decide if the benefits clearly outweigh the potential risks to you and your baby. If you are a woman of childbearing age, it is advised to avoid pregnancy while using Entyvio. Safe contraception should be used during treatment and for at least 4.5 months after the last treatment. Breastfeeding: Talk to your doctor if you are breastfeeding or planning to breastfeed. Entyvio passes into breast milk. There is not enough information about its effect on your baby and milk production. Considering the benefits of breastfeeding for your baby and the benefits of treatment for you, a decision should be made to stop breastfeeding or stop treatment with Entyvio. Usage instructions: Always use this medicine exactly as your doctor or pharmacist has told you. Contact your doctor or pharmacist if you are not sure. You or your caregiver will be trained on how to inject Entyvio subcutaneously (under the skin). How much Entyvio you should get: The treatment with Entyvio is similar to ulcerative colitis and Crohn's disease. The recommended dose is 108 mg of Entyvio by subcutaneous injection every two weeks. At the start of treatment, your doctor will give you the first doses of Entyvio by infusion into a vein in your arm (intravenous infusion) for about 30 minutes. After at least 2 infusions into the vein, you can start receiving Entyvio as a subcutaneous injection. The first injection is given during the next scheduled intravenous infusion and then every two weeks thereafter. Entyvio injection: The first injection can be given by yourself or a caregiver after you have been trained on how to do it. Instructions are at the end of the package leaflet. If you forget to give or miss using Entyvio: If you forget or miss a dose, the next dose should be injected as soon as possible then every two weeks. If you stop treatment with Entyvio: Do not stop treatment with Entyvio without first talking to your doctor. Ask your doctor or pharmacist or nurse if you have any questions about using this medicine. Ingredients: Vedolizumab 180 mg. Product details: Brand: Entyvio, Product model: prefilled injection pen, Product type: prefilled injection pen.

Questions you might have

‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌